

(19) World Intellectual Property
Organization
International Bureau



553816

(43) International Publication Date
11 November 2004 (11.11.2004)

PCT

(10) International Publication Number
WO 2004/097423 A1

- (51) International Patent Classification⁷: **G01N 33/68**
- (21) International Application Number:
PCT/EP2004/004342
- (22) International Filing Date: **23 April 2004 (23.04.2004)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/465,484 25 April 2003 (25.04.2003) US
- (71) Applicant (for all designated States except US): **GENOVA LTD.**; Canon's Court, 22 Victoria Street, Hamilton, HM 12, Bermudas (BM).
- (71) Applicant (for AT only): **NOVARTIS PHARMA GmbH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BOUGUELERET, Lydie** [FR/CH]; GeneProt, Inc., 2, Pre-de-la-Fontaine, CH-1217 Meyrin (CH). **CUSIN, Isabelle** [FR/CH]; GeneProt, Inc., 2, rue Pre-de-la-Fontaine, CH-1217 Meyrin (CH).
- (74) Agent: **GRUBB, Phillip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report

[Continued on next page]

(54) Title: **SECRETED POLYPEPTIDE SPECIES REDUCED CARDIOVASCULAR DISORDERS**

SEQ ID NO:1

1 MTLVSVLMY LGSFLFLGAD TARLDVASEF RKKWNKWALS RGRRELMSS SYPTGLADV
61 AGPAQTLIRP QDMGASRSP EDSSPDAARI RVKRYRQSMN NFQGLRSFGC RFGTCTVQKL
121 AHQIYQFTDK DKDNVAPRSK ISPQGYGRRR RRLPPEAGPG RTLVSSKPQA HGAPAPPSGS
181 APHFL

SEQ ID NO:2

1 ARLDVASEFR KKNKWALSR GKRRLRMSSS YPTGLADVKA GPAQTLIRPQ DMGASRSP
61 DSSPDAARIR VKRYRQSMN FQGLRSFGCR PGTCTVQKLA HQIYQFTDKD KDNVAPRSKI
121 SPQGYGRRR RSLPEAGPGR TLVSSKPQAH GAPAPPSGSA PHFL

SEQ ID NO:3

ELRMSSSYPT GLADVKAQPA QTLIRPQDMK GASRSPEDSS PDAARIRV

SEQ ID NO:4

MSSSYPTGLA DVKAGPAQTL IRPQDMK

SEQ ID NO:5

MSSSYPTGLA DVK

SEQ ID NO:6

AGPAQTLIRP QDMK

(57) Abstract: The invention discloses human secreted polypeptides that circulate at a decreased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and treatment of cardiovascular disorders.

WO 2004/097423 A1



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.